Cleansing Notice — Rights Issue

Sep 24, 2018
Posted in: Investor updates

Home » Cleansing Notice — Rights Issue

Cleansing Notice — Rights Issue

Sep 24, 2018
Posted in: Investor updates

Imagion Biosystems has lodged Pro-Rata Non-Renounceable Rights Issue: Notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth) with the Australian Securities Exchange.
View the Pro-Rata non-Renounceable Rights Issue announcement.

Quarterly Activity Report – Quarter ending 31 December 2023

January 31, 2024

Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal

[VIDEO] EGM Recording – 13 November 2023

November 14, 2023

https://youtu.be/hThLkmpJPW0 EGM 13 November 2023 Video transcript: Welcome and thanks for joining us. Both those joining virtually and those in person. As the time is

Quarterly Activity Report – Quarter ending 30 September 2023

October 31, 2023

Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Cleansing Notice — Rights Issue

Cleansing Notice — Rights Issue

Related Articles

Quarterly Activity Report – Quarter ending 31 December 2023

[VIDEO] EGM Recording – 13 November 2023

Quarterly Activity Report – Quarter ending 30 September 2023

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list